Agios Pharmaceuticals (AGIO) Long-Term Deferred Tax (2012 - 2013)
Agios Pharmaceuticals (AGIO) reported Long-Term Deferred Tax of $2.7 million for Q3 2013, little changed quarter-over-quarter from $2.7 million in Q2 2013.
Agios Pharmaceuticals (AGIO) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Agios Pharmaceuticals has reported Long-Term Deferred Tax for 2 years, with the latest figure at $2.7 million in Q3 2013.
- For the quarter ending Q3 2013, Long-Term Deferred Tax changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Sep 2013 stood at $2.7 million (changed N/A YoY), and the FY2012 full-year result was $2.7 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q3 2013 stood at $2.7 million, roughly flat from $2.7 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $2.7 million in Q4 2012, with the low at $2.7 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 2.71 Mn |
| Jun 30, 2013 | 2.71 Mn |
| Dec 31, 2012 | 2.71 Mn |